Digest Network Come funziona
Network
/
Società
Br
Non verificato

Bristol Myers Squibb

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

125 comunicati stampa

Guarda tutti i comunicati
09/03/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
07/03/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
02/03/2026
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Bristol Myers Squibb Announces Dividend
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
26/02/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
23/02/2026
Eventi
Web e Social Network
Biotecnologia
Sanità
Farmaceutica
Salute
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
23/02/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
17/02/2026
Oncologia
Igiene alimentare
Salute
Farmaceutica
Cardiologia
Biotecnologia
Industria
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
05/02/2026
Associazioni/Professionisti
Salute
Finanza
Sanità
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
04/02/2026
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
03/02/2026
Mercato del lavoro
Industria
Biotecnologia
Sanità
Farmaceutica
Salute
Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0